Second Quarter 2025 Earnings Call August 5, 2025 These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause ...

Core Insights - Myriad Genetics is presenting new clinical data on its Precise MRD test for oligometastatic clear-cell renal cell carcinoma (ccRCC) at the AACR Annual Meeting, highlighting its potential in precision medicine [1][4] Group 1: Clinical Data and Findings - The study indicates that metastasis-directed radiation therapy (MDT) can delay or avoid systemic treatments without compromising overall survival, with survival rates of 94% at two years and 87% at three years [4] - The Precise MRD test identified over 50% of patients as MRD-positive at baseline, which is significant given the low tumor fractions typical in ccRCC that often evade detection by earlier MRD tests [4][3] - Patients who tested negative on Precise MRD maintained MDT for a median of 54 months, compared to 27 months for those who tested positive, suggesting a longer duration before initiating aggressive therapy [4] Group 2: Technology and Methodology - Myriad's Precise MRD test is an ultrasensitive, tumor-informed assay that detects circulating tumor DNA (ctDNA) in plasma, utilizing large panels to enhance sensitivity [3][5] - The test employs a novel ranking algorithm to select up to 1,000 high-confidence targets, optimizing panel design for residual disease detection [4] - Including insertion/deletion (INDEL) mutations in MRD panels improves the likelihood of detecting low abundance ctDNA, enhancing sensitivity at low tumor concentrations [4] Group 3: Future Directions and Applications - Myriad continues to develop the Precise MRD assay for various applications, with ongoing evaluations in high-impact studies [4][5] - The company aims to meet the needs of cancer patients, academic partners, and biopharma companies through its advanced testing solutions [6][7]